Scientific Presentations

Home OCT & Notal OCT Analyzer
The Macula Society Meeting 2024 | February 2024

Home OCT Guided Management of Neovascular AMD Patients up to 12 Months

Jeff Heier, MD
The Macula Society Meeting 2024 | February 2024

Clinical Utility of Home OCT Data in Management of Neovascular Age Related Macular Degeneration

Michael Elman, MD
The Macula Society Meeting 2024 | February 2024

Home Optical Coherence Tomography Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study

Daniel Martin, MD
Angiogenesis, Exudation and Degeneration Conference 2024 | February 2024

Home OCT Guided Management of Patients with nAMD

Nancy Holekamp, MD
Angiogenesis, Exudation and Degeneration Conference 2024 | February 2024

Longitudinal AI-based Fluid Quantification and its Implication for Remote Patient Monitoring

Anat Loewenstein, MD

SCANLY Home OCT FDA Intended Use

SCANLY Home OCT has not been approved by FDA for use other than described in the following Intend Use: The Notal Vision Home Optical Coherence Tomography (OCT) System is an Artificial Intelligence (AI)-based Home Use device indicated for visualization of intraretinal and subretinal hypo-reflective spaces in a 10 by 10-degrees area centered on the point of fixation of eyes diagnosed with neovascular age-related macular degeneration (NV-AMD). In addition, it provides segmentation and an estimation of the volume of hypo-reflective spaces. The Notal Home OCT device is intended for imaging at home between regularly scheduled clinic assessments and not intended to be used to make treatment decisions or replace standard-of care regularly scheduled examinations and clinical testing as needed, including in-office imaging and assessments for changes in vision, by an ophthalmologist.

See also Warnings and Precautions.

ForeseeHome FDA Intended Use

ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

Media enquiries? Reach out to our Media Contact